Literature DB >> 12817769

Study designs in osteoporosis.

Robert J Temple1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12817769     DOI： 10.1359/jbmr.2003.18.6.1129

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN： 0884-0431            Impact factor:   6.741


× No keyword cloud information.
  4 in total

1.  Recommendations for an update of the current (2001) regulatory requirements for registration of drugs to be used in the treatment of osteoporosis in postmenopausal women and in men.

Authors:  Jean-Yves Reginster; Eric Abadie; Pierre Delmas; René Rizzoli; Willard Dere; Philippevan der Auwera; Bernard Avouac; Maria-Luisa Brandi; Anastasia Daifotis; Adolfo Diez-Perez; Gonzalo Calvo; Olof Johnell; Jean-Marc Kaufman; Gottfried Kreutz; Andrea Laslop; Fritz Lekkerkerker; Bruce Mitlak; Per Nilsson; John Orloff; Mary Smillie; Andrew Taylor; Yannis Tsouderos; Dominique Ethgen; Bruno Flamion
Journal:  Osteoporos Int       Date:  2005-08-10       Impact factor: 4.507

2.  Evidence of sustained vertebral and nonvertebral antifracture efficacy with ibandronate therapy: a systematic review.

Authors:  Silvano Adami; Luca Idolazzi; Maurizio Rossini
Journal:  Ther Adv Musculoskelet Dis       Date:  2011-04       Impact factor: 5.346

3.  Denosumab in men receiving androgen-deprivation therapy for prostate cancer.

Authors:  Matthew R Smith; Blair Egerdie; Narciso Hernández Toriz; Robert Feldman; Teuvo L J Tammela; Fred Saad; Jiri Heracek; Maciej Szwedowski; Chunlei Ke; Amy Kupic; Benjamin Z Leder; Carsten Goessl
Journal:  N Engl J Med       Date:  2009-08-11       Impact factor: 91.245

Review 4.  A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate.

Authors:  Jean-Yves Reginster; Dieter Felsenberg; Cyrus Cooper; Jacob A Stakkestad; Paul D Miller; David L Kendler; Silvano Adami; Michael R McClung; Michael A Bolognese; Roberto Civitelli; Etienne Dumont; Bernard Bonvoisin; Robert R Recker; Pierre D Delmas
Journal:  Osteoporos Int       Date:  2005-06-14       Impact factor: 4.507
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.